Le Lézard
Classified in: Science and technology
Subject: MRR

New Zealand Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics Databook 2024: A US$1.3 Billion Market by 2028


DUBLIN, March 29, 2024 /PRNewswire/ -- The "New Zealand Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2024 Update" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The gift card industry in New Zealand is expected to reach US$1 billion in 2024 and continue to grow to reach US$1.3 billion by 2028.

The gift card market in 2023 was driven a wide range of factors, which supported growth across retail and corporate segments. The primary factors included growth of ecommerce, increased adoption to incentivize employees working remotely, digital gifting, and initiatives undertaken by government, hospitality, and travel industries to revive growth.

This report provides a detailed data centric analysis of gift card market, covering market opportunities and risks across a range of retail categories. With over 75 KPIs at country level, this report provides a comprehensive understanding of gift card market dynamics, market size and forecast.

Companies Featured

Key Report Benefits:

Report Scope

Total Spend on Gifts in New Zealand

Gift Card Market Size by KPIs across Consumer Segments in New Zealand

Gift Card Market Size by Consumer Segment in New Zealand

Digital Gift Card Market Size in New Zealand

Gift Card Market Size by Retail Consumer in New Zealand

Gift Card Spend by Consumer Behavior and Demographics in New Zealand

Gift Card Market Size by Corporate Consumer in New Zealand

Gift Spend by Product Categories (Split by Retail and Corporate Consumers) in New Zealand

Gift Card Spend by Retail Sector (Split by Retail and Corporate Consumers) in New Zealand

Gift Card Spend by Distribution Channel (Split by Retail and Corporate Consumers) in New Zealand

Gift Card Sales Estimates by Key Retailers

For more information about this report visit https://www.researchandmarkets.com/r/x2ottc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected] 
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

SOURCE Research and Markets


These press releases may also interest you

at 02:43
January-March 2024 Net sales, which for the quarter only included royalties, amounted to SEK 156 (520)Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact.Earnings per share before...

at 02:35
Valtech, the global leader in Experience Innovation, has today completed its acquisition of the digital transformation consultancy Kin + Carta. This strategic investment cements Valtech's position as the first-choice business transformation partner....

at 02:27
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:22
Gausium, a leading innovator in robotic cleaning technology, is set to display its latest fleet of smart floor cleaning robots and unveil its floor coating solutions at the upcoming Interclean show located in RAI Amsterdam, 14-17 May 2024....

at 02:05
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...



News published on and distributed by: